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ABsTRAcT
Heterozygous mutations in the transcription factor gene p63 are causative for several 
syndromes with ectodermal dysplasia, orofacial clefting and limb malformations as the 
key characteristics. Different combinations of these features are seen in five different 
syndromes, of which ectrodactyly, ectodermal dysplasia and cleft lip/palate syndrome 
(EEC) is the most common one. Mutations in p63 can also cause non-syndromic single 
malformations, such as split hand foot malformation (SHFM4) and isolated cleft lip 
(NSCL). In this article we will present an overview of diseases caused by mutations in the 
p63 gene and review the known pathogenic p63 gene mutations.
InTRoducTIon
The	transcription	factor	p63	is	a	key	regulator	of	ectodermal,	orofacial	and	limb	devel-
opment.	This	became	apparent	in	1999,	by	the	generation	of	p63	knockout	mice1,2	and	
by	the	finding	of	dominant	mutations	in	human	disorders	with	ectodermal	dysplasia,	split	
hand/foot	malformation	and	orofacial	 clefting.3-7	Mutations	 in	 the	p63	 gene	 can	cause	
at	 least	 five	 different	 syndromes:	 ectrodactyly,	 ectodermal	 dysplasia	 and	 cleft	 lip/palate	
syndrome	 (EEC,	 OMIM	 604292),	 ankyloblepharon-ectodermal	 defects-cleft	 lip/palate	
syndrome	 (AEC,	 OMIM	 106260),	 limb	 lammary	 syndrome	 (LMS,	 OMIM	 603543),	
acro-dermato-ungual-lacrimal-tooth	 syndrome	 (ADULT,	 OMIM	 103285)	 and	 Rapp-
Hodgkin	 syndrome	 (RHS,	OMIM	129400).	Furthermore,	 two	non-syndromic	human	
disorders	are	caused	by	p63	mutations:	 isolated	split	hand/foot	malformation	(SHFM4,	
OMIM	 605289)	 and	 recently	 non-syndromic	 cleft	 lip.8	 Here	 we	 present	 an	 overview	
of	 these	 seven	 p63-linked	 conditions,	 the	 genotype-phenotype	 associations	 and	 give	 an	
update	of	all	known	pathogenic	p63	mutations.
p63 pHenoType 
Ectodermal	dysplasia	(ED)	is	one	of	the	three	main	characteristics	of	the	p63-associ-
ated	syndromes	(Fig.	1).	Ectodermal	dysplasia	manifests	as	the	abnormal	development	or	
growth	of	tissues	and	structures	that	are	developed	from	the	outer	embryonal	layer,	ecto-
derm.	In	this	condition	skin,	hair,	teeth,	nails	and	several	exocrine	glands,	such	as	sweat	
and	sebaceous	glands	are	usually	abnormally	developed.	The	epidermis	of	p63	patients	can	
be	very	dry,	itchy	and	hypopigmented.	In	extreme	cases	widespread	areas	of	the	skin	can	
be	erosed	often	including	the	scalp.	This	is	most	common	in	the	AEC	syndrome,	where	
patients	 present	 patches	 of	 life-threatening	 congenital	 skin	 erosion.	 However,	 the	 skin	
usually	recovers	after	the	first	year.	The	amount	of	scalp	and	body	hair	is	often	diminished	
and	hair	can	be	wiry	or	curly.	Alopecia	is	sometimes	reported.	Occasionally	the	eyelashes	
and	eyebrows	are	also	absent.	The	number	of	teeth	is	often	less	than	in	healthy	individuals,	
indicating	that	there	is	a	reduced	number	of	teeth	placodes.	Teeth	can	also	be	malformed	
by	 a	 conical	 shape	 and	 poor	 enamel	 formation,	 causing	 subsequent	 tooth	 decay.	 Nails	
can	be	dystrophic,	thickened	and	discoloured.	The	absence	or	reduced	amount	of	sweat	
glands	is	also	reported	among	p63	patients	and	leads	to	diminished	perspiration,	which	
can	be	life-threatening.	Mammary	gland	and	nipple	hypoplasia	are	other	manifestations	
of	the	ectodermal	dysplasia	spectrum	observed	in	p63	patients.	Also	the	development	and	
function	of	sebaceous	and	salivary	glands	are	frequently	abnormal.	Lacrimal	duct	defects	
and	obstruction	of	the	lacrimal	ducts	impose	a	risk	for	conjunctivitis	and	corneal	damage.	
Characteristics	of	ED	described	here	varies	between	the	p63	syndromes	and	even	within	a	
one	single	syndrome,	as	will	be	discussed	below	in	this	article.
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Split	 hand/foot	 malformation	 (SHFM)	 constitutes	 the	 second	
part	 of	 the	 p63	 syndrome	 phenotype	 (Fig.	 1).	 Hands	 and	 feet	 are	
often	malformed	and	have	a	severe	median	cleft	in	the	palm	and/or	in	
the	sole.	These	clefts	usually	occur	in	conjunction	with	a	lack	of	one	
or	more	central	(2-3-4)	digits,	which	is	called	ectrodactyly.	Fusion	of	
fingers	or	toes,	which	is	called	syndactyly,	can	be	seen	in	conjunction	
with	ectrodactyly.	In	most	cases	SHFM	is	part	of	a	syndrome,	but	it	
can	also	be	present	in	isolation,	without	other	symptoms.	
The	 third	 hallmark	 of	 p63	 syndrome	 phenotype	 is	 orofacial	
clefting	(Fig.	1).	It	is	mainly	seen	in	the	form	of	cleft	lip	(CL)	and/
or	cleft	palate	 (CP).	This	 symptom	is	usually	observed	as	part	of	a	
complex	 syndrome,	 where	 other	 organs	 are	 also	 affected,	 however,	
recently	 Leoyklang	 et	 al.8	 have	 described	 mutations	 in	 p63	 gene	
causing	orofacial	clefting	as	the	only	abnormality.	
Most	 of	 the	 above	 developmental	 defects	 are	 also	 observed	 in	
p63	 knockout	 mice,	 which	 have	 particular	 severe	 defects	 of	 ecto-
dermal	 structures	 and	 the	 limbs.1,2	 Heterozygous	 p63+/-	 mouse	
have	 no	 significant	 developmental	 abnormalities,	 suggesting	 that	
loss-of-function	of	one	allele	 is	not	disease-causing.	Recently,	 it	has	
been	 reported	 that	a	high	proportion	of	p63+/-	 aging	mice	develop	
tumours	indicating	a	role	of	p63	in	tumour	suppression.9	However,	
this	observation	could	not	be	confirmed	in	an	independent	study.10	
There	is	no	indication	that	individuals	with	heterozygous	p63	muta-
tion	are	prone	to	develop	tumours.
AllelIc p63 condITIons
EEC syndrome.	The	prototype	of	the	p63	syndrome	family	is	the	
EEC	syndrome	(Fig.	1).	EEC	syndrome	patients	are	invariably	char-
acterized	by	one	or	more	features	of	ectodermal	dysplasia,	which	can	
present	as	defects	of	hair,	skin,	nails,	teeth	and	glands.	The	severity	
and	type	of	 the	ectodermal	 features	 is	highly	variable,	and	to	some	
extent	dependent	on	 the	exact	nature	of	 the	mutation	 (see	below).	
Only	 few	 patients	 show	 defects	 in	 all	 of	 the	 described	 ectodermal	
structures	 above.	 EEC	 patients	 occasionally	 also	 have	 mammary	
gland/nipple	 hypoplasia	 (14%)	 and	 hypohidrosis	 (11%).	 About	
two-thirds	of	these	patients	have	ectrodactyly,	and	syndactyly	is	also	
frequent	(43%).	Cleft	lip/palate	is	present	in	about	40%	of	the	EEC	
patients,	mostly	as	CL	with	or	without	CP.11
EEC	syndrome	is	mainly	caused	by	point	mutations	in	the	DNA	
binding	 domain	 (DBD)	 of	 the	 p63	 gene	 (Table	 1).	 Altogether	 34	
different	mutations	have	been	reported,	and	20	different	amino	acids	
are	 involved.	 Only	 two	 mutations	 are	 outside	 the	 DNA	 binding	
domain:	one	insertion	(1572	InsA)	and	one	point	mutation	(L563P)	
in	the	sterile	a	motif	domain	(SAM).4,11	In	earlier	studies	we	found	
five	frequently	mutated	amino	acids:	R204,	R227,	R279,	R280	and	
R304	 in	 the	 EEC	 population,	 all	 located	 in	 CpG	 islands	 (Fig.	 2).	
These	 five	 mutations	 explain	 almost	 90%	 of	 the	 EEC	 syndrome	
patients.11,12	The	five	p63	arginine	hotspot	mutations	and	probably	
also	other	DNA	binding	domain	mutations	that	are	found	in	EEC	
syndrome	appear	to	impair	the	p63	protein	binding	to	DNA.4	The	
autosomal	dominant	inheritance	of	EEC	syndrome	suggests	that	the	
EEC	 mutations	 have	 a	 dominant	 negative	 effect.	 However,	 recent	
genotype-phenotype	analyses	for	the	five	hotspot	mutations	revealed	
significant	 differences	 between	 the	 corresponding	 phenotypes.	 For	
instance	 cleft	 lip/palate	 is	 present	 in	 the	 R304	 mutation	 popula-
tion	 (80%),	 whereas	 R227	 patients	 seldom	 have	 cleft	 lip/palate.	
Syndactyly	is	completely	absent	in	R227	population,	while	30-60%	
of	the	other	hotspot	mutation	population	have	syndactyly.	Genito-
urinary	defects	are	frequently	observed	in	R227	mutation	population	
(40%),	while	significantly	less	in	other	populations.11	It	thus	seems	
that	 these	 hotspot	 mutations	 exert	 specific	 effects.	 Such	 specificity	
might	be	brought	 about	by	different	 effects	 of	 these	mutations	 on	
promoters	 for	 p63	 transcriptional	 target	 genes.	 Alternatively,	 these	
hotspot	mutations	may	exhibit	gain-of-function	effects,	similar	as	for	
the	p53	hotspot	mutations.13
Limb mammary syndrome (LMS).	The	LMS	phenotype	resembles	
the	EEC	syndrome	phenotype,	but	the	ectodermal	manifestations	are	
milder	(Fig.	1).3	A	consistent	feature	of	LMS	is	the	mammary	gland	
and/or	 nipple	 hypoplasia	 (100%).	 Lacrimal	 duct	 obstruction	 and	
dystrophic	nails	are	frequently	observed	(59	and	46%	respectively),	
hypohydrosis	and	teeth	defects	are	detected	in	about	30%,	but	other	
ectodermal	defects	 such	as	hair	and	skin	defects	are	 rarely	detected	
if	 at	all.	About	70%	of	LMS	patients	have	 similar	 limb	malforma-
tions	as	in	EEC	syndrome,	and	about	30%	orofacial	clefting,	notably	
always	in	form	of	cleft	palate.11
Mutations	in	LMS	are	 located	in	the	N-	and	C-terminus	of	the	
p63	gene	(Table	1).	A	large	LMS	family	(29	affected	members)	has	a	
point	mutation	in	exon	4,	causing	a	G76W	substitution	in	the	DN-
specific	 putative	 transactivation	 domain	 (TA2).3,12,14,15	 One	 other	
point	mutation	(S90W)	is	also	located	between	the	TA	domain	and	
DBD.	Other	LMS	mutations	are	reported	in	the	C-terminus:	a	TT	
deletion	 in	 the	 exon	13	 and	an	AA	deletion	 in	 exon	14.6,12	These	
will	affect	only	the	p63a	protein	isoforms,	where	they	are	predicted	
to	cause	a	frame	shift	and	a	premature	stop	codon.	Also	a	stop	muta-
tion	in	the	transcription	factor	inhibitory	domain	(TI)	(K632X)	has	
been	identified	in	a	sporadic	LMS	patient.11	The	latter	mutation	is	
predicted	to	impair	the	suppressive	effect	of	the	TI	domain	towards	
the	TA	domain,	thus	increasing	the	transactivation	activity.16
ADULT syndrome.	ADULT	syndrome	phenotype	is	most	similar	
to	 LMS	 syndrome,	 although	 clear	 differences	 can	 be	 seen	 when	
Figure 1. Various combinations of ectodermal dysplasia, orofacial clefting 
and limb malformations are the hallmark of p63-associated syndromes. EEC 
syndrome is the prototype of these syndromes and together with LMS shows 
all three hallmarks. ADULT syndrome patients never show orofacial clefting, 
whereas AEC and RHS never show limb defects. Non-syndromic limb defect 
condition (SHFM4) and non-syndromic cleft lip/palate (NSCL) are also 
caused by mutations in the p63 gene.
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Table 1 Pathogenic p63 mutations in seven allelic diseases
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observing	larger	families	or	patient	populations.	The	main	difference	
is	the	absence	of	orofacial	clefting	and	the	presence	of	hair	and	skin	
defects	in	the	ADULT	syndrome	(Fig.	1).	Teeth,	skin	and	nail	defects	
are	 constantly	 present	 in	 ADULT	 syndrome	 (100,	 93	 and	 100%,	
respectively),	but	only	rarely	in	LMS.	Hair	(53%)	and	lacrimal	duct	
defects	(67%)	are	observed	in	ADULT	patients	more	frequently	than	
in	LMS.	Freckling	has	been	reported,	but	cannot	be	considered	to	be	
a	differentiating	feature	of	this	syndrome.17
By	 today,	 four	 ADULT	 syndrome	 families	 and	 three	 sporadic	
cases	have	been	reported.17-23	All	the	families	and	one	of	the	sporadic	
cases	have	a	point	mutation	in	exon	8,	changing	R298	in	the	DNA	
binding	domain	into	either	a	glutamine	or	a	glycine	(Table	1).	While	
EEC	syndrome	mutations	in	the	DNA	binding	domain	impair	the	
binding	of	p63	protein	to	DNA,4	arginine	298	is	not	located	close	to	
the	DNA-binding	interface,	and	mutation	of	this	arginine	does	not	
affect	 DNA	 binding.21	 Instead,	 earlier	 studies	 have	 shown	 a	 gain-
of-function	 effect	 for	 the	mutated	DNp63g	 isoform,	which	usually	
does	not	have	a	transactivation	activity	in	assays	using	an	optimized	
p53-responsive	element.17,21	Two	other	mutations	are	located	in	the	
N-terminus:	 N6H	 mutation	 affects	 only	 the	 DN-isoforms	 and	 in	
another	isolated	patient	a	missense	mutation	G134D*	is	located	just	
front	of	the	DBD	in	exon	4.20,23
AEC syndrome.	The	AEC	syndrome	phenotype	differs	from	the	
other	 conditions	mainly	by	 the	 severity	of	 the	 skin	phenotype,	 the	
occurrence	of	an	eyelid	fusion	at	birth	and	the	absence	of	limb	malfor-
mations	(Fig.	1).	Approximately	80%	of	the	patients	have	severe	skin	
erosion	at	birth,	which	usually	will	 recover	 in	 the	 first	years	of	 the	
life.	 The	 eyelid	 fusion,	 also	 called	 ankyloblepharon,	 is	 present	 in	
about	45%	of	AEC	patients,	but	only	rarely	in	other	p63-associated	
conditions.	The	other	ED	symptoms,	such	as	nail	and	teeth	defects	
are	present	 in	more	 than	80%	of	patients,	 and	hair	defects	 and/or	
alopecia	are	almost	constant	features	(94%).	Lacrimal	duct	obstruc-
tion	is	seen	in	50%	of	patients,	whereas	mammary	gland	hypoplasia	
and	 hypohydrosis	 occur	 occasionally	 (both	 13%).	 Interestingly,	
almost	40%	of	patients	have	hearing	impairment	and	genito-urinary	
defects.	Cleft	 lip	 is	present	 in	44%	and	cleft	palate	 in	about	80%.	
Limb	malformations	are	almost	absent.	Ectrodactyly	has	never	been	
reported,	but	25%	of	patients	has	only	mild	syndactyly.11
Rapp-Hodgkin syndrome (RHS).	RHS	mimics	AEC	very	much	
(Fig.	 1).	The	 differences	 discussed	 earlier	 in	 several	 papers	 are	 the	
absence	of	ankyloblepharon	in	RHS	and	the	more	severe	skin	pheno-
type	in	AEC.11,24	Other	ED	symptoms,	such	as	orofacial	clefting	and	
the	near	absence	of	 limb	malformations	are	 similar	 to	AEC.	These	
two	conditions	could	be	considered	as	a	single	entity,	since	the	anky-
loblepharon	is	present	only	in	about	45%	of	AEC	syndrome	patients,	
and	therefore	is	not	a	discriminating	factor.	Although,	the	severity	of	
the	skin	phenotype	is	obvious	and	more	severe	in	AEC	patients	than	
in	RHS	patients,	the	strong	overlap	between	AEC	and	RHS	suggest,	
that	they	are	variable	manifestations	of	the	same	clinical	entity.11,24
AEC	and	Rapp	Hodgkin	syndrome	mutations	are	located	in	the	
C-terminus	of	the	p63	protein	(Fig.	2).	They	are	either	point	muta-
tions	 in	 the	SAM	domain	or	deletions	 in	 the	SAM	or	TI	domains	
(Table	1).7,11,12,24-35	The	SAM	domain	is	known	to	be	involved	in	
protein-protein	interactions	and	therefore	mutations	in	this	domain	
are	 most	 probably	 hampering	 the	 binding	 to	 interacting	 proteins.	
One	 known	 interactor	 of	 p63	 SAM	 domain	 is	 the	 Apobec-1-
binding	protein-1	(ABBP1),	which	is	a	member	of	RNA	processing	
machinery	 and	 known	 to	 regulate	 the	 alternative	 splicing	 of	 the	
Fibroblast-growth-factor-receptor-2	 (FGFR2)	 towards	 the	 epithe-
lial	 specific	 isoform.	 AEC	 mutations	 in	 the	 SAM	 domain	 abolish	
the	 binding	 to	 ABBP1,	 which	 most	 probably	 leads	 to	 changes	 in	
FGFR2	 RNA	 splicing.36	 Interestingly,	 gain-of-function	 mutation	
Figure 2. Pathogenic p63 mutations cause at least five different syndromes and two non-syndromic conditions. Mutations causing different diseases are 
illustrated in different colours. Only mutations that are discussed in the text are indicated, an overview of all mutations is given in Table 1. EEC hotspot 
mutations are clustered in DNA binding domain, and RHS and AEC syndrome mutations in SAM and TI domains. Several mutations, such as R280, R313, 
I510, S541 and 1850 Del A, can have a variable clinical outcome, probably due to genetic background effects. The black asterisks illustrate sites needed 
for upiquitination (K193, K194 and PY) and the white asterisk represents a sumoylation site (fKXD/E).40,42,58
 
*In the article incorrect amino acid annotation, erratum pending ref. Slavotinek
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in	FGFR2	gene	have	been	reported	in	a	number	of	craniosynostosis	
syndromes,	 which	 are	 also	 characterized	 by	 distal	 limb	 malforma-
tions.37	 Recently,	 loss-of-function	 mutations	 in	 FGFR2	 have	 been	
found	in	lacrimo-auricolo-dento-digital	syndrome	(LADD),	an	ED	
syndrome	characterized	by	dominant	inheritance	of	 limb	defects	 in	
association	with	abnormal	lacrima,	ear	cups	and	teeth.38	Interestingly,	
LADD	shows	marked	overlap	with	EEC	syndrome,	and	was	earlier	
also	presumed	to	be	caused	by	mutations	in	the	p63	gene.
non-syndRomIc p63 condITIons
Split	hand/foot	malformation	type	4	(SHFM4)	is	a	“pure”	 limb	
malformation	(ectrodactyly	and	syndactyly)	condition,	thus	without	
orofacial	 clefting	 or	 ectodermal	 dysplasia.	 The	 non-syndromic	
SHFM4	 is	 caused	 by	 several	 mutations,	 which	 are	 dispersed	
throughout	 the	 p63	 gene:	 a	 point	 mutation	 in	 the	 transactivation	
domain	(TA)	(R58C),	a	splice-site	mutation	in	front	of	exon	4	(3’ss	
intron	 4),	 four	 missense	 mutations	 in	 the	 DNA	 binding	 domain	
(K193E,	K194E,	R280C,	R280H),	and	two	nonsense	mutations	in	
the	TI-domain	(Q634X,	E639X)	(Table	1).5,6,39	It	is	still	unclear	how	
these	widely	dispersed	mutations	cause	the	limb	defect.	Interestingly,	
several	 SHFM4	 mutations	 are	 reported	 to	 cause	 alteration	 in	 the	
p63	protein	activation	and	stability:	Q634X	and	E639X	are	known	
to	disrupt	 the	 sumoylation	 site,	 and	 therefore	 increase	 the	 stability	
and	transcriptional	activity	of	 the	p63a	 isoform.40,41	Furthermore,	
amino	acids	K193	and	K194	are	required	for	ubiquitin	conjugation	
by	E3	ubiquitin	 ligase	 (Itch)	 and	naturally	 occurring	mutations	 in	
those	amino	acids	cause	more	stable	p63	protein.42	Possibly,	SHFM	
is	 caused	 by	 altered	 protein	 degradation,	 even	 though	 different	
degradation	routes	are	 involved.	Another	divergent	phenomenon	is	
the	R280C/H	mutations,	which	are	not	only	causative	for	SHFM4,	
but	also	for	the	syndromic	EEC	phenotype	in	other	families.	In	such	
families,	the	phenotype	is	always	consistent,	either	EEC	or	SHFM4.	
In	SHFM4	families	decreased	penetrance	is	reported,	for	the	R280	
mutation,	suggesting	an	effect	of	a	nearby	genetic	modifier.
Recently,	a	non-syndromic	orofacial	clefting	type	was	also	linked	
to	p63	gene.8	The	amino	acid	change	R313G	is	 the	 first	mutation	
causing	 the	 non-syndromic	 cleft	 lip/palate	 (NSCL)	 phenotype	 in	
the	p63	gene.8	This	mutation	was	also	observed	in	a	sporadic	EEC	
syndrome	phenotype	(authors’	unpublished	data).	Mutations	and/or	
polymorphisms	 in	3	other	 genes,	 IRF6,	MSX1	 and	PVRL,	 are	 also	
associated	with	a	 syndromic	and	non-syndromic	 forms	of	orofacial	
clefting.43-49	In	the	study	of	Leoyklang	et	al.8	also	other	changes	in	
the	p63	gene	were	found	(N87N,	S90L,	L248L,	H406H,	D564H),	
but	because	the	mutations	did	not	change	the	amino	acid	sequence	
or	were	 also	 found	 in	one	of	 the	healthy	parents	or	 in	 the	 control	
population,	 they	 were	 not	 considered	 to	 be	 pathogenic	 changes.	
Nevertheless,	since	orofacial	clefts	are	considered	to	have	a	multifac-
torial	origin	 it	 is	quite	possible	 that	 these	 changes	 in	 the	p63	 gene	
impose	a	 risk	 factor	 for	 facial	clefting	 type,	 similar	as	was	 reported	
for	the	IRF6	gene.	
dIscussIon
The	mutation	patterns	 in	the	p63	gene,	that	are	associated	with	
different	p63	clinical	conditions	display	a	clear	genotype-phenotype	
association:	especially	in	the	EEC	and	AEC/RHS	syndromes,	where	
mutations	 are	 clustered	 in	 the	 DNA	 binding	 domain	 and	 in	 the	
SAM	 and	TI	 domains,	 respectively.	 In	 about	 250	 patients	 we	 and	
others	 have	 described	 74	 different	 mutations	 causing	 five	 different	
syndromes	 and	 two	 different	 non-syndromic	 conditions.	This	 still	
increasing	number	of	patients	allows	 the	delineation	of	 the	pheno-
typic	and	genotypic	pictures	of	different	p63-associated	disorders.	In	
addition,	 evidence	 is	 accumulating	 that	other	genetic	 factors	 influ-
ence	the	final	p63	mutant	phenotype.	
Several	 examples	 show	 that	 the	 same	 mutation	 can	 lead	 to	
different	 clinical	 conditions.	 AEC	 and	 RHS	 syndromes	 share	 three	
mutations:	 I510,	 S541	 and	 1859	 Del	 A.24,25,28,29,31,33	 Often	 the	
clinical	distinction	between	RHS	and	AEC	syndrome	is	solely	based	
on	the	presence	or	absence	of	ankyloblepharon,	which	in	fact	is	not	
the	discriminating	feature	between	these	two	conditions.11	Also	LMS	
and	 ADULT	 syndrome	 seem	 to	 be	 caused	 by	 the	 same	 mutation	
G134D	(authors’	unpublished	data),23	as	well	as	EEC	syndrome	and	
non-syndromic	cleft	lip/palate	due	to	the	R313G	mutation	(authors’	
unpublished	 data).8	 Also	 several	 frameshift	 mutations	 are	 found,	
interestingly	 always	 with	 variable	 phenotype,	 thus	 causing	 EEC,	
LMS,	AEC	or	RHS	 syndrome.	The	possible	 explanation	may	be	a	
misdiagnose	in	sporadic	cases,	because	of	the	phenotypic	variability,	
likely,	however	frameshift	mutations	are	exceptionally	sensitive	to	the	
effects	 of	 modifier	 genes.	 An	 example	 of	 family-dependent	 clinical	
phenotype	 is	 the	arginine	280	mutation,	which	can	be	mutated	 to	
cysteine	or	histidine	and	lead	either	to	the	non-syndromic	SHFM4	
(2	 families)	 or	more	often	 to	 syndromic	 ectodermal	dysplasia	with	
SHFM	and	orofacial	clefting	(EEC)	(9	families).5,6,26,50	Surprisingly,	
the	penetrance	is	reduced	in	SHFM	families,	but	not	in	EEC	fami-
lies,	 which	 also	 indicates	 a	 modifier	 effect	 somewhere	 else	 in	 the	
genome.	
The	 phenotypic	 variation	 between	 the	 p63-linked	 diseases	 is	
large,	furthermore	the	phenotypic	variation	within	one	disease	is	also	
considerable.	It	is	clear	that	variability	within	families	may	be	ascribed	
to	 a	 combination	 of	 modifier	 genes,	 and	 stochastic	 processes.	 No	
such	modifier	genes	have	yet	been	identified	for	the	p63	syndromes	
described	 in	 this	 review.	 However,	 modifiers	 have	 been	 identified	
for	the	phenotypic	effects	of	p53	gene	mutations	in	human	cancer,	
and	at	 least	one	of	these	has	also	been	shown	to	affect	p63	protein	
levels	and	transcription.51,52	Other	candidate	modifier	genes	may	be	
found	in	pathways	that	are	known	to	affect	specific	phenotypes.	For	
instance,	genetic	variation	in	the	IRF6	gene	could	be	tested	as	a	risk	
factor	for	cleft	lip	in	p63	mutant	families.47-49	
Furthermore,	variation	between	families	likely	reflects	differential	
downstream	 effects	 for	 each	 of	 these	 mutations.	 There	 are	 many	
possible	ways	 in	which	 this	 can	be	 achieved,	 as	 the	p63	protein	 is	
expressed	in	several	isoforms,	which	are	involved	in	different	cellular	
functions	during	the	embryonal	development	but	also	later	on.	The	
variation	in	the	phenotypes	caused	by	each	of	the	five	EEC	hotspot	
mutations	 is	 also	 striking.	The	EEC	hotspot	mutation	data,	where	
clear	 phenotypic	 variation	 is	 seen	 between	 the	 mutations	 inside	 a	
single	clinical	syndrome,	might	reflect	that	different	target	genes	are	
affected	by	each	of	the	hotspot	mutations.	Whether	this	is	so,	needs	
to	be	examined	in	more	detail	in	animal	models	or	cellular	systems.	
Clearly,	these	EEC	mutations	cannot	just	be	simple	loss-of-function	
or	 dominant	 negative	 mutations,	 but	 gain-of	 function	 mutations	
are	likely	involved,	as	was	described	for	p53	mutations	in	transgenic	
mice.53-55	
Finally,	the	finding	that	some	mutations	such	as	R280C/H	have	
different	 phenotypes	 between	 families,	 but	 the	 same	 phenotype	
consistently	within	families	suggest	the	influence	of	cis-acting	poly-
morphisms,	 either	 in	p63	 itself	 or	within	 a	 genetically	 linked	gene	
on	 chromosome	 3q.	 Such	 functional	 polymorphisms	 have	 not	 yet	
been	described,	but	here	too,	 there	are	precedents	 for	 the	existence	
of	 such	 polymorphisms	 in	 both	 p53	 and	 p73.56,57	 Each	 of	 these	
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possible	mechanisms	 for	 phenotypic	modulation	will	 require	 func-
tional	hypotheses	 that	can	be	verified	 in	experimental	 systems,	and	
ultimately	be	 tested	 for	 their	 impact	on	 the	many	 families	 that	are	
affected	by	these	clinically	often	severe	malformations.
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